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ABSTRACT
Research into non-hormonal, alternative therapies is necessary for women for whom menopausal hor-
mone therapy is contraindicated or for women who do not wish to take hormones. This review focuses
on one such non-hormonal option, namely, purified and specific cytoplasmic pollen extract, or
PureCyToninVR . This extract has been evaluated in several preclinical and clinical studies, where it demon-
strated its value as a safe and non-estrogenic alternative for menopause. This review presents the benefi-
cial effects of PureCyToninVR in the treatment of menopausal symptoms (e.g. hot flushes) in healthy
women, as well as in premenstrual syndrome. We discuss the mechanism of action of PureCyToninVR , an
SSRI-‘like’ therapy. The lack of estrogenic effect demonstrated in preclinical studies suggests that
PureCyToninVR may also be a suitable option for the management of menopausal symptoms in women
with breast cancer.
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Introduction
The life expectancy of women in developed countries has
increased by more than 30 years during the last century.
Consequently, menopause has become a natural event in a wom-
an’s life. Menopause is characterized by loss of reproductive
function and decline in estrogen levels [1,2] and may be associ-
ated with multiple symptoms such as hot flushes, night sweats,
sleep disturbances, decreased libido, sexual dysfunction, poor
memory, anxiety/depression, and urinary incontinence, all of
which may constitute indications for therapeutic intervention.
Hot flushes are a thermoregulatory disorder due to a lack of
estrogens. They are the most characteristic and distressing symp-
toms of menopause and have been reported to affect over 75%
of middle-aged women [3]. Menopausal hormone therapy
(MHT) is an established and effective option for hot flushes in
menopausal women. However, it is contraindicated in conditions
such as estrogen-dependent diseases and acute thromboembolic
events. Adherence to hormone therapy is frequently not satisfac-
tory. Since the primary and negative outcomes of the large-scale
US clinical trial MHT of the Women’s Health Initiative (WHI)
Study in 2002, the number of MHT prescriptions has dropped
drastically.
While regulatory bodies in Europe and the USA recommend
that MHT should be used for as short a time as possible, some
clinical guidelines recommended less restrictive prescribing.
However, for women for whom MHT is contraindicated or who
do not wish to take hormones, research into alternative therapies
is clearly necessary. These include non-hormonal options, which
may be non-pharmacological or pharmacological. Non-pharma-
cological interventions include lifestyle changes, behavioral thera-
pies, holistic techniques, food supplements, and herbal therapies
[4]. Pharmacological interventions include anti-depressants, anti-
hypertensive drugs, and anti-epileptics [5,6].
This review focuses on PureCyToninVR , which is the main
ingredient of the food supplement SerelysVR . SerelysVR is natural in
origin and constitutes a non-hormonal alternative for the treat-
ment of hot flushes and other menopausal symptoms. Its value
and safety in the treatment of menopausal hot flushes and in
premenstrual syndrome (PMS) has been demonstrated in several
preclinical in vitro and in vivo studies and in clinical trials.
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Background
Pollen (from the Greek -akg [pale]: flour or dust) constitutes
the male gametophyte of the flower. It is composed of minuscule
ovoid grains measuring 20–55lm in diameter that are initially
contained at the end of stamens and are surrounded by a shell
called an exine. The function of this pollen shell is to protect the
genetic material. Well-known allergens are located on the exter-
nal shell, whereas the center of the pollen contains the cytoplasm
[7]. Germination occurs when the pollen is transported by wind
or bees to a compatible female pistil. The male gametophyte pro-
duces a pollen tube that transfers the sperm to the egg, which
contains the female gametes. Pollen has long been used for
therapeutic purposes by various civilizations (e.g. Ancient Egypt
and China, as far back as 200 BC). The chemical composition of
pollen depends largely on the plant source and geographic ori-
gin, together with factors such as climatic conditions, soil type,
and the activity and race of the bees. However, since pollen may
be of unspecific origin (from unknown plants) and may be
mixed with other bee products, standardization is difficult [8]. In
addition, when the grain is unopened, its components can be
partially assimilated because the pollen shell cannot be damaged
by stomach acid [9,10]. The shell proteins are meant to be highly
allergenic [9,10]. Go^sta Carlsson, a Swedish gynecologist, is con-
sidered the ‘father’ of the pollen extraction method. In the 1940s,
he took an empirical approach to this field, with the hypothesis
that the administration of pollen extracts could return strength
and vigor to elderly patients.
Production of purified and specific cytoplasmic pollen
extract: PureCyToninVR
Today, the extraction procedure for purified and specific cyto-
plasmic pollen extract under the trademark of PureCyToninVR
(removed from its allergenic shell) enables retention of the active
pollen components. PureCyToninVR is the main ingredient of the
food supplement SerelysVR , which is a combination of purified
pollen/pistil cytoplasmic extracts. The pollen and pistils come
from selected plants belonging to the Gramineae family and/or
Pinaceae family and are harvested separately using a standar-
dized method. Cultivation and harvesting take place in fields that
are separated by plant type in accordance with the recommenda-
tions of the European Medicines Agency. The fields are free of
pesticides and the chemical molecules usually used for plant
growth and of any possible contamination. Manufacture of
PureCyToninVR includes procedures that destroy the allergenic
components of pollen. Allergens are broken down into peptides
and amino acids. In the process, the pollen shells are completely
removed, thus minimizing the risk of allergic reactions. The pro-
duction procedures are standardized to ensure that batches of
cytoplasmic pollen extract are reproducible. High-performance
liquid chromatography (HPLC) and gas chromatography can
verify that the group of compounds which forms the active sub-
stance is consistent between each batch. These extracts contain
entities such as proteins, amino acids, sugar, minerals, vitamins,
and fats. The amino acids, in particular, can be identified using
analytical methods. Tryptophan, a precursor of serotonin, has
been documented to be present in the pollen of the plants from
which PureCyToninVR is extracted [11].
The method described makes it possible to exclude any aller-
gen, thus ensuring that PureCyToninVR is safe to use. In addition,
the exclusion of the shell, which constitutes a very stable protect-
ive pollen wall, makes the active compounds highly bioavailable
[9,10]. Pollen extracts are water-soluble, and several compounds
in the water-soluble pollen extracts are suitable. These include
nutrients such as amino acids, carbohydrates, and minerals, as
previously described [9,10]. However, no specific PK/PD data are
available, and further studies should be performed. With a stand-
ardized extract blending procedure, 160mg of PureCyToninVR
and pollen/pistil extract is the main component of SerelysVR , with
a recommended daily dose of 320mg. SerelysVR has been used in
Europe since at least 1995. A search on PubMed reveals a variety
of commercial names: SerelysVR , FemalVR , FemalenVR , Femelis
MenoVR , MenolesseVR , SansageVR , and RelizenVR . In France, it has
received marketing authorization, under the name of Femelis, as
a traditional herbal medicine used to relieve the symptoms of
the menopause.
Preclinical studies with purified and specific
cytoplasmic pollen extract: PureCyToninVR
PureCyToninVR has been evaluated in several preclinical studies,
where it demonstrated its value as a safe and non-estrogenic
alternative for menopausal symptoms (Table 1).
PureCyToninVR has been tested for acute oral toxicity. It was
given to 10 mice at a single dose of 2000mg/kg. The mice were
followed for 2 weeks. All the animals survived, with no signs of
toxicity, thus indicating that PureCyToninVR is very safe and non-
toxic when given orally at a single high dose to these ani-
mals [12,13].
An OECD-approved genotoxicity test (the Ames test) has also
been performed with PureCyToninVR to determine potential
mutagenic activity. The Ames test uses bacteria to test whether a
given product can cause mutations in the DNA of the test organ-
ism. It therefore serves as a quick and convenient assay to esti-
mate the carcinogenic potential of a compound. The potential of
PureCyToninVR for inducing reverse gene mutations has been
examined, although no mutagenic activity was observed when
the product was assessed using the Ames test [14,15]. A non-
mutagenic extract is generally considered to have no carcino-
genic potency and does not need to be further investigated for
carcinogenesis.
Several in vitro and in vivo tests demonstrated that
PureCyToninVR has no estrogenic action. A detailed study of the
phytoestrogen composition by HPLC analysis revealed no trace
of genistein, formononetin, or biochanin A, although it did show
very minimal sub-effective concentrations of daidzein and genis-
tein in these pollen extracts, thus ruling out any estrogenic
action of pollen extracts.
Compared with ethinyl estradiol, PureCyToninVR did not show
any uterotrophic effect in immature female rats when the utero-
trophic screening assay was applied in juvenile Wistar rats [16].
No estrogenic effect was demonstrated in a reporter gene assay
using human embryonic kidney 293T cells that were co-trans-
fected with estrogen receptors ER alpha and ER beta and a luci-
ferase reporter plasmid containing ER response elements.
Compared with 17-b estradiol, PureCyToninVR was not able to
induce transcriptional activation through the estrogen recep-
tors [17].
The human breast cancer cell line MCF7 endogenously
expresses estrogen receptors and has been widely used for the
study of estrogenic compounds. These cells were used to test
whether an estrogenic effect of pollen extract led to proliferation.
PureCyToninVR did not show any effect on cell proliferation in
MCF7 cells up to the highest concentration tested [17].
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Recently, PureCyToninVR , was analyzed to determine whether
a small breast cancer risk may exist by stimulating steroidal
receptors other than nuclear estrogen receptors, such as proges-
terone receptor membrane component (PGRMC1). Receptor
membrane-initiated actions of PureCyToninVR were compared
with estradiol (E2) and growth factors (IGF, FGF, EGF) in two
different breast epithelial cancer cells (MCF7 and TD47) trans-
fected with PGRMC1. The response of hormone receptor-posi-
tive breast cancer cells to estradiol (E2) and growth factors took
the form of an increased proliferation rate and downregulation
of apoptosis. PureCyToninVR was neutral in the cell lines trans-
fected or not transfected with PGRMC1 in terms of cell prolifer-
ation and cell apoptosis compared to estradiol and growth
factors. It was also neutral in combination with estradiol and
growth factors in the two parameters tested. The authors con-
clude that the reduction in symptom scores reported from post-
menopausal women treated with SerelysVR may not be mediated
by estrogen or estrogen-like pathways [18]. PureCyToninVR did
not interfere with the efficacy of tamoxifen since it does not
inhibit CYPD26, the enzyme which metabolizes tamoxifen to its
active metabolite [19].
The data set out above support those reported by Espie [17]
and recently by Biglia et al. [20] and Capozzi and Lello [21],
who concluded that pollen extract is a non-estrogenic alternative
for managing menopausal symptoms in cancer survivors.
SerelysVR in menopause: clinical data
SerelysVR has proven efficacious for the treatment of vasomotor
symptoms in several clinical trials, including placebo-controlled
trials, a clinical trial comparing treatment with MHT, and open-
label studies (Table 2).
A randomized double-blind placebo-controlled study showed
a significant reduction in hot flushes compared with placebo
after 3 months. A total of 64 menopausal women were moni-
tored during an initial phase of 1 month, during which their
menopausal symptoms were recorded. This phase was followed
by a 3-month period in which one group received SerelysVR (at a
rate of two tablets per day), while the other group received pla-
cebo. Sixty-five percent of women treated with SerelysVR
responded with a reduction in hot flushes compared with 38% in
the placebo group (p< .006). In the Menopausal Rating Scale
(MRS) evaluation, there was a 23% reduction in hot flushes in
women taking SerelysVR compared with placebo after 2 months.
The reduction was 22% after 3 months. There was also an
improvement in tiredness, dizziness, mood, libido, headache,
irritability, mood swings, and sensitiveness in the SerelysVR group
compared with baseline (p< .031) [22].
In the same study, no differences were found in the hormone
profiles of the two treatment groups, both of which had the
expected high levels of FSH and low levels of estrogen. In add-
ition, there were no changes in the level of SHBG or testoster-
one [22].
An open study conducted in France with 417 women taking
SerelysVR for 3 months showed an improvement or reduction in
menopausal symptoms. The frequency of hot flushes was
reduced by 65% (intensity by 64%), sweating and perspiration by
66% (intensity by 67%), irritability by 54%, and fatigue by 51%.
Quality of life and tolerance were considered excellent in peri-
menopausal and menopausal women [23].
In a subanalysis, perimenopausal and menopausal women
were assessed separately for tolerance and effectiveness of
SerelysVR . SerelysVR proved to be very efficacious in many of the
parameters analyzed, and tolerance was excellent in 92% of the
patients [24]. In another study, standardized pollen extract was
Table 1. In vitro and in vivo analysis with purified and specific cytoplasmic pollen extract: PureCyToninVR .
Type of study Study Publication/report Type of measurement Main results
No estrogenic
activity
HPLC analysis Hellstrom et al. (2012) A detailed study of phytoestrogen
composition
No trace of phytoestrogens
Estrogenic activity with
uterotrophic
screening assay
Hellstrom et al. (2012) Uterotrophic screening assay in
juvenile Wistar rats
No uterotrophic effect in vivo
compared with estradiol/no
estrogenic activity
Reporter gene assay in 293T
cells. Cell proliferation in
MCF7 cells
Espie M., IMS World
Congress – Poster (2014)
Espie (2013)
Transcriptional activation through
the estrogen receptors ER a or ER
b with an ERE-luc cotransfection
Proliferation was determined by the
MTT test
No affinity for estrogen receptors ER
a and ER b/no estrogenic activity
No proliferation on breast cancer
cell line
Proliferation and apoptosis
MCF7 TD47 breast cancer
cell line with PGRMC1
Comparison with estradiol
(E2) and growth factors
Seeger et al. (2017) MCF-7 and T47D cells were
transfected with PGRMC1
Different concentrations of pollen
extract alone and in combination
with E2 or growth factor were
tested
Proliferation was determined using
the MTT test
Apoptosis was determined using
the CDD ELISA kit
PureCyToninVR was neutral in the cell
lines alone or in combination
with E2 or growth factors in
terms of cell proliferation and cell
apoptosis, both in cells
transfected with PGRMC1 and in
cells not transfected
with PGRMC1
Potential interaction
with tamoxifen
Goldstein et al. (2015) Potential inhibition of CYPD26
enzyme at high concentrations in
pooled liver microsome with
quinidine as a control
No inhibition of CYPD26 with
PureCyToninVR 6.53–10%
compared with quinidine, which
inhibits 100%
Potential mode
of action
Selective serotonin reuptake
inhibition, genomic study
Appel et al., GREM 2020,
1. in press.
Effects of PureCyToninVR on the
uptake of [3H]-serotonin into rat
cortical synaptosomes
RNA sequencing profile in SH-SY5
Y cells
Inhibition of the uptake of [3H]-
serotonin into rat cortical
synaptosomes in a dose-
dependent manner
Neuropeptides and
neurotransmitters genes are
differentially modulated
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associated with an improvement in perimenopausal symptoms
such as hot flushes and mood swings [25].
D’Alterio et al. [26] showed benefits for peri- and post-meno-
pausal neurovegetative symptoms in a clinical trial where women
were treated with SerelysVR , estrogen/progestin therapy, or pla-
cebo for 6 months. This study confirmed efficacy in reducing the
intensity of the neurovegetative symptoms of menopause. The
reduction in the Kupperman index was slightly lower, but similar
to that of estrogen/progestin therapy.
Quality of life and reduction in hot flushes were recently
assessed in Poland in an open-label study that demonstrated effi-
cacy with respect to the resolution of vasomotor symptoms after
as few as 4 weeks of treatment; this effect increased during the
subsequent months as well. The benefits of SerelysVR in peri-
menopausal women are multidirectional in nature and pertain to
many somatic and nonsomatic elements responsible for the qual-
ity of life [27].
A prospective observational study to evaluate the efficacy and
safety of SerelysVR in the management of women with meno-
pausal symptoms was performed in 104 women in the Czech
Republic. This study showed a significant decrease in various
menopausal symptoms from baseline through 12 weeks
(p< .0001). Hot flushes were reduced by 48.5%, sleep disturban-
ces by 50.1%, depressive mood by 51.2%, irritability by 47.9%,
and fatigue by 47.8%. Menopausal symptoms were reduced sig-
nificantly, with very few side effects [28].
Taken together, these data show that PureCyToninVR is an
effective non-hormonal, non-pharmacological therapy for the
management of hot flushes and menopausal symptoms.
Compared with non-pharmacological interventions and other
non-hormonal treatments, it is effective and safe in women who
do not wish to take MHT and women for whom MHT is contra-
indicated, e.g. women with breast cancer who turn to natural
supplements and remedies for relief.
In the 2015 position statement of the North American
Menopause Society on non-hormonal management of meno-
pause-associated vasomotor symptoms, pollen extract was already
classified as ‘Over-the-counter supplements and herbal therapies’.
However, in this position statement, only one randomized con-
trolled trial in menopause was evaluated [6,22]. In France, mar-
keting authorization has been granted under the name Femelis
as a traditional herbal medicine used to relieve the symptoms
of menopause.
Although PureCyToninVR is not yet universally approved
according to the main guidelines, the studies documented in this
review point to PureCyToninVR as a non-estrogenic alternative for
managing menopausal symptoms. It can also be administered in
cancer survivors. The purpose of this review is to improve the
Table 2. Clinical trials with SerelysVR in menopause.
Type of clinical trial
Author and year
of publication Type of measurement Main results
Randomized double-blind
placebo-controlled
Winther et al. (2005) 64 women double blind placebo-controlled
trial
3 months of treatment
MRS, 15 Quality of life QoL parameters
15 QoL parameters
Diary of AUB
Blood samples for FSH, E2, TT, SHBG
65% of women responded, with a reduction
in hot flushes compared with 38% in the
placebo group (p<.006). 54 women were
analyzed. The MRS evaluation revealed a
23% reduction in hot flushes with
SerelysVR compared with placebo after 2
months, and a 22% reduction after 3
months.
Improvement in tiredness, dizziness, mood,
libido, headache, irritability, mood swings,
and sensitiveness) in the SerelysV
R
group
compared with baseline (p<.031)
No changes in vaginal dryness parameter
No AUB
No change in blood levels of FSH, E2,
TT, SHBG
Randomized placebo-
controlled compared
with MHT
D’Alterio et al. (2015) 45 women randomly treated either with
SerelysVR or with estrogen/progestin
therapy or with placebo for 6 months.
Evaluation at day 0, day 60, and day 90.
The reduction in the Kupperman index
was used for evaluation
Efficacy was slightly lower but similar to that
of the estrogen/progestin therapy in peri
and postmenopausal
neurovegetative symptoms.
Open-label study Elia et al. (2008) 417 women in France treated for 3 months,
questionnaire and VAS evaluation at day
0 and day 90
The frequency of hot flushes was reduced
by 65% (intensity by 64%), sweating and
perspiration by 66% (intensity by 67%),
irritability by 54%, and fatigue by 51%.
Open-label study Druckman et al. (2015) 324 women. Analysis of efficacy and
tolerance in perimenopausal and
menopausal women. Evaluation at day 0
and day 90 through VAS.
Improvement in QoL by 53–72%.
Reduction of intensity of menopausal
symptoms in peri and menopausal
women. No differences observed for
either group.
Open-label Study Paczkowski et al. (2018) Quality of life in 50 women and reduction in
hot flushes were assessed in an open
study with the Menopause Rating Scale
(MRS) and Female Sexual Functioning
Inventory (FSFI) at 3 visits
Shows very good efficacy of the product
with respect to elimination of vasomotor
symptoms as early as after 4 weeks of
treatment. This effect increased during
the subsequent months of treatment.
Open-label study Fait et al. (2019) 104 women in the Czech Republic treated
for 3 months and evaluated with the
Menopause Rating Scale (MRS) at day 0,
day 30, day 60, and day 90
Significant decrease in menopausal
symptoms between the starting point of
the study and after 12 weeks (p<.0001).
Hot flushes were reduced by 48.5%, sleep
disturbances by 50.1%, and depressive
mood by 51.2%.
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quality of care by generating and disseminating information on
pollen extract that can help to diversify professional practices.
Therefore, PureCyToninVR and the finished product, SerelysVR ,
could be recommended in the guidelines of the main gyneco-
logical societies as a non-hormonal alternative for the manage-
ment of menopausal symptoms and to improve patients’ quality
of life.
Clinical data on SerelysVR in premenstrual symptoms
Premenstrual syndrome often includes symptoms such as anx-
iety, irritability, depression, loss of confidence, mood swings, and
fatigue. There are also physical symptoms, typically bloating,
water retention, and breast pain. It is the timing, rather than the
types of symptoms, and the degree of impact on daily activity
that supports a diagnosis of PMS. The symptoms, which may
severely affect quality of life, occur during the 2 weeks before
menses, and some signs continue during menstruation before
disappearing a few days afterwards [29]. These manifestations
can occur in women from their late 20s to their early 40s and
have a negative impact on their professional, social, and sexual
lives. PMS is caused by changes in normal hormone levels that
can induce disorders in the central neuroendocrine system. It is
well established that serotonin plays a role in PMS, as some
selective serotonin reuptake inhibitors (SSRIs) have a beneficial
impact on premenstrual disorders. A meta-analysis of all avail-
able randomized controlled trials involving SSRIs used in PMS
confirmed these to be more efficacious than placebo [30–32].
PureCyToninVR has been proven to be beneficial for the man-
agement of PMS in various randomized, double-blind, placebo-
controlled clinical trials (Table 3). One randomized double-blind
placebo-controlled cross-over trial showed the efficacy of
SerelysVR in women with PMS. The study included 32 women.
Group A received two SerelysVR tablets twice daily for two con-
secutive cycles, whereas group B received placebo for two cycles.
Groups A and B were then crossed over: those taking the pla-
cebo took the active product, and vice versa. Two months of
active treatment lowered overall symptom indices significantly
and lowered six of nine individual symptom scores by 27–57%.
Symptoms (e.g. irritability, swelling, weight fluctuation, and
mood swings) improved significantly in women with PMS when
they took the active product (p< .05). Evidence for a slow onset
of action and protracted effect was provided by the finding that
all symptom indices studied declined significantly (by 48–88%)
in the group that received placebo before active treatment
(p< .01). Premenstrual weight gain was reduced by 50% in
patients receiving active treatment compared with placebo. There
were no reported unwanted or adverse effects during active treat-
ment [33].
Another randomized double-blind placebo-controlled multi-
center trial looked at the efficacy of SerelysVR in PMS: 50 women
taking two tablets of the active product per day were compared
with 51 women on placebo. The study duration was four cycles.
Compared with placebo, SerelysVR was associated with a signifi-
cant improvement in PMS symptoms, particularly in sleep dis-
turbances. This reduction was further observed in women who
reported irritability as their major PMS symptom (p< .001).
There were no differences in adverse events in the active treat-
ment group compared with placebo [34].
Winther et al. [35] confirmed these results in a recent sub-
analysis in which women with PMS symptoms were separated
depending on whether the predominant symptom was irritability
or dysphoria. The authors showed that in patients reporting irrit-
ability as their main PMS symptom, SerelysVR significantly low-
ered PMS indicators, as reflected in global scores in both
observer-based and self-evaluation scoring of symptoms.
Mechanism of action of SerelysVR
During the menopause transition, neuronal cells, neurotransmit-
ters, neuropeptides, and neurosteroids in the central nervous sys-
tem (CNS) undergo important changes as a consequence of
fluctuations in the levels of hormones such as estrogen [36].
These changes could be responsible for the generation of hot
flushes and modifications in behavior, cognition, and mood.
There is evidence of a neuroendocrine origin and a key role of
neurotransmitters (e.g. glutamate, gamma-aminobutyric acid
(GABA), serotonin (5-hydroxytryptamine [5-HT]), dopamine,
acetylcholine noradrenaline), since some of the known treat-
ments for hot flushes and modifications in behavior, cognition,
and mood are compounds that modulate these neurotransmitters
[37,38]. SSRIs are used for their known effect on thermoregula-
tion and sleep quality, by acting on serotonergic neurons.
Recently, a specific type of neurons – KNDy kisspeptin/neuroki-
nin B/dynorphin neurons – have been shown to be present in
the hypothalamus at the level of the preoptic area. These change
dramatically in postmenopausal women, in whom they can gen-
erate hot flushes [39]. In this subpopulation of neurons, in par-
ticular, neurokinin B and its receptor NK3R have been
implicated in the induction of hot flushes in healthy women that
are typical in location and duration of postmenopausal hot
flushes [40,41]. In order to gain more insights into the mechan-
ism of action of SerelysVR on neurons, the effect of
PureCyToninVR on the uptake of [3H]-serotonin into rat cortical
Table 3. Clinical trials with SerelysVR in premenstrual symptoms.
Type of clinical trial
Author and year of
publication Type of measurement Main results
Randomized double-blind
placebo-controlled
Winther et al. (2002) 32 women treated either with SerelysVR for
2 consecutive cycles or placebo for
2 consecutive cycles. Groups A and B were
then swapped over: those taking the placebo
took the active product and vice versa
Efficacy in women with premenstrual
syndrome irritability, swelling, weight
fluctuation, mood swings, etc. were
significantlyreduced (p< .05).
Randomized double-blind
placebo-controlled
Gerhardsen et al. (2008) Multicenter study with 101 women treated
either with SerelysV
R
or placebo for 4 cycles.
This improvement was observed mainly for
the ‘irritability’ symptom (p< .001).
Randomized double-blind
placebo-controlled
Winther et al. (2018) Sub-analysis of 101 women in 2 groups: one
reported irritability as their main PMS
symptom the other reported dysphoria as
their main PMS symptom
Daily intake of 30mg of SerelysVR for 4 cycles
led to a 50% reduction in various PMS
symptoms in patients with irritability as
their main symptom. The reduction was
versus placebo. Such a reduction was not
seen in the dysphoria group.
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synaptosomes was analyzed. PureCyToninVR inhibited the uptake
of [3H]-serotonin into rat cortical synaptosomes in a dose-
dependent manner. The EC50 value of 60 lg/ml is well within a
physiologically achievable order of magnitude. Inhibition of sero-
tonin uptake may therefore play a role in the physiological action
of SerelysVR [42]. PureCyToninVR could act as an SSRI-like ther-
apy, potentially without the known adverse effects of SSRIs.
Additionally, tryptophan, a precursor of serotonin, is present in
the pollen of the plants from which PureCyToninVR is extracted
[11]. The average level of tryptophan in pollen extracts measured
in Serelys tablets is about 0.09mg/tablet [43]. Taking these obser-
vations together, pollen extract appears to maintain the availabil-
ity of serotonin in hypothalamic serotonergic neurons, and this
could explain in part the efficacy of the extract in controlling
thermoregulation, sleep, and mood in menopausal women. There
are also dopaminergic neurons located in the frontal cortex, the
nucleus accumbens, the hippocampus, and the striatum. These
dopaminergic neurons are responsible for pleasure, mood, motiv-
ation, and perseverance [44]. Decreased levels of estradiol in
postmenopausal women may reduce dopaminergic neurotrans-
mission and impair cognitive and motor functions [45].
A genomic study was performed in neurons to further inves-
tigate which pathways are modulated by PureCyToninVR and
better understand its correlation with beneficial biological
effects [42]. The human cell line SH-SY5Y, which comprises
cells differentiated by all-trans-retinoic acid (RA), has long
been used to study neuronal signaling pathways modulated by
chemical entities. RA treatment induces differentiation of these
proliferating cells to cells with a cholinergic neuron phenotype
exhibiting neuron-like properties, including neurite, and
expressing cholinergic neuronal markers. In this study, the cells
were treated with or without PureCyToninVR , and mRNA
extracted from SH-SY5Y cells was analyzed with mRNA-seq
profiling. Significantly modulated genes underwent pathway
analysis using the software application Ingenuity Pathway
Analysis (Qiagen, Germantown, MD) to identify pathways of
interest that could be modified by pollen extract. Preliminary
results show several modulated genes that may correlate with
the beneficial effects induced by PureCyToninVR in menopausal
women. These include the dopamine D2 receptor (DRD2),
which was significantly modulated [42]. DRD2 is implicated in
several domains, including motivation, pleasure, cognition,
memory, learning, and fine motor control, as well as in modu-
lation of neuroendocrine signaling. Interestingly, it has been
shown that estradiol activates the transcription of DRD2 in the
frontal cortex and increases the level of DRD2 mRNAs. DRD2
declines substantially during a person’s lifetime, and animal
studies have shown age-related reductions in dopamine release
and dopamine markers in the cerebral cortex [46]. Decreased
levels of estradiol in post-menopausal women may reduce the
expression of D2 receptors, thus contributing to reduced dopa-
minergic neurotransmission and impairment of cognitive and
motor functions. Hence, this increased expression in DRD2
induced by pollen extract may benefit menopausal women.
Current analysis is focusing on other genes coding for neuro-
peptides implicated in nociceptive pain, cognition, feeding, and
various regulatory processes (waking and sleep, mood, blood
pressure, osmosis, and water intake). In one study, pollen
extract increased the expression of protective enzymes such as
NQO1, an antioxidant enzyme that exerts its effect by scaveng-
ing superoxide to shield against oxidative stress actuated by
cytotoxic substances. This action could provide additional cyto-
protection and prove especially effective in tissues with low
levels of superoxide dismutase expression in pro-oxidant envi-
ronments. It has been shown that the marked reduction in
estrogen during menopause increases levels of oxidative stress
in the body [47]. Part of the mechanism of action of
PureCyToninVR could also be explained by its antioxidant activ-
ity. Compared with other approaches, pollen extracts have been
shown to exhibit superoxide dismutase activity in the gener-
ation of oxygen free radicals [48].
Conclusions
SerelysVR is an effective and safe non-hormonal alternative for
alleviating menopausal symptoms without increasing the risk of
breast cancer in women in whom MHT is contraindicated or
who do not wish to use hormones. SerelysVR has proven to be
safe and efficacious. It improves hot flushes, sleep disturbances,
and nervousness in menopausal women. The beneficial effects
are also observed in PMS. These findings seem to correlate with
the effect of its main ingredient, PureCyToninVR , on inhibition of
the reuptake of serotonin and other neurotransmitters. Current
studies are being performed to fully determine the mode of
action of PureCyToninVR .
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